FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rury Holman

Research Profile

Disorders

Chemicals & Drugs

Geographic Areas

Great Britain

Concepts & Ideas

Activities & Behaviors

Fasting

Co-author Network

Publications

TOP 3
Richard J Stevens; B J Cairns; Rury R Holman
Metformin and mortality. Reply to Lund SS [letter].
Timothy M E Davis; Rury R Holman; Ruth L Coleman
Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
Rury R Holman
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rury Holman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Richard J Stevens; B J Cairns; Rury R Holman
Metformin and mortality. Reply to Lund SS [letter].
Diabetologia 2013;56(4):939-40.
2013: Timothy M E Davis; Rury R Holman; Ruth L Coleman
Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
Circulation 2013;127(9):980-7.
2013: Rury R Holman
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive.
Nature reviews. Endocrinology 2013;9(2):67-8.
2012: John J V McMurray; Robert M Califf; Steven M Haffner; Rury R Holman
Prediabetes and the risk of diabetes.
Lancet 2012;380(9849):1225-6; author reply 1226.
2012: John J V McMurray; Angelyn M Bethel; Robert M Califf; Steven M Haffner; Rury R Holman
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(10):731.
2012: Richard J Stevens; G Viberti; R Ali; C R Bankhead; M A Bethel; B J Cairns; R P Camisasca; F L Crowe; Andrew Farmer; S Harrison; J A Hirst; P Home; S E Kahn; J H McLellan; Rafael Perera; Annette Plüddemann; A Ramachandran; N W Roberts; Peter W Rose; A Schweizer; Rury R Holman
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
Diabetologia 2012;55(10):2593-603.
2012: Tomoaki Shimizu; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; David M Nathan; Robert Sherwin; Bernard Zinman
[Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes].
Nihon rinsho. Japanese journal of clinical medicine 2012;70 Suppl 3():591-601.
2012: H Sourij; Rury R Holman
Women develop diabetes at higher BMIs than men.
Diabetologia 2012;55(3):855-6.
2012: David Preiss; Guy E Rutten; Eberhard Standl; Jie Lena Sun; Laine E Thomas; Gianni Tognoni; Robert M Califf; Fu-Tien Chiang; Steven M Haffner; Rury R Holman; Lawrence A Leiter; Felipe A Martinez; Theodore Mazzone; John J McMurray
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
BMJ open 2012;2(6):.
2011: N Jenkins; Nina Hallowell; Andrew Farmer; Rury R Holman; J Lawton
Participants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study.
Diabetic medicine : a journal of the British Diabetic Association 2011;28(5):543-8.
2011: John M Lachin; Gitanjali Paul; Giancarlo Viberti; Bernard Zinman; R Paul Aftring; Steven M Haffner; William H Herman; Rury R Holman; Steven E Kahn; Barbara G Kravitz
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Clinical journal of the American Society of Nephrology : CJASN 2011;6(5):1032-40.
2011: Steven E Kahn; John M Lachin; Bernard Zinman; Steven M Haffner; R Paul Aftring; Gitanjali Paul; Barbara G Kravitz; William H Herman; Giancarlo Viberti; Rury R Holman
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Diabetes 2011;60(5):1552-60.
2011: H C Price; S J Griffin; Rury R Holman
Impact of personalized cardiovascular disease risk estimates on physical activity-a randomized controlled trial.
Diabetic medicine : a journal of the British Diabetic Association 2011;28(3):363-72.
2011: Julia Lawton; Nicholas Jenkins; Julie L Darbyshire; Rury R Holman; Andrew Farmer; Nina Hallowell
Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial.
Trials 2011;12():108.
2010: Nicholas Jenkins; Nina Hallowell; Andrew J Farmer; Rury R Holman; Julia Lawton
Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences.
Diabetes care 2010;33(10):2178-80.
2010: Hermione C Price; Philip M Clarke; Alastair M Gray; Rury R Holman
Life expectancy in individuals with type 2 diabetes: implications for annuities.
Medical decision making : an international journal of the Society for Medical Decision Making 2010;30(3):409-14.
2010: Richard Kahn; Peter Alperin; David Eddy; Knut Borch-Johnsen; John Buse; Justin Feigelman; Edward Gregg; Rury R Holman; M Sue Kirkman; Michael P Stern; Jaakko Tuomilehto; Nick J Wareham
Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
Lancet 2010;375(9723):1365-74.
2010: Henry Krum; John J V McMurray; Edward Horton; Teresa Gerlock; Bjoern Holzhauer; Lineke Zuurman; Steven M Haffner; M Angelyn Bethel; Rury R Holman; Robert M Califf
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Cardiovascular therapeutics 2010;28(2):124-32.
2010: Bernard Zinman; Steven M Haffner; William H Herman; Rury R Holman; John M Lachin; Barbara G Kravitz; Gitanjali Paul; Nigel P Jones; R Paul Aftring; Giancarlo Viberti; Steven E Kahn
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2010;95(1):134-42.
2010: Steven E Kahn; Steven M Haffner; Giancarlo Viberti; William H Herman; John M Lachin; Barbara G Kravitz; Dahong Yu; Gitanjali Paul; Rury R Holman; Bernard Zinman
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Diabetes care 2010;33(1):177-83.
2009: Hermione C Price; Christina Dudley; BA Barrow; Simon J Griffin; Rury R Holman
Perceptions of heart attack risk amongst individuals with diabetes.
Primary care diabetes 2009;3(4):239-44.
2009: Rury R Holman; Andrew Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Three-year efficacy of complex insulin regimens in type 2 diabetes.
The New England journal of medicine 2009;361(18):1736-47.
2009: Julie L Darbyshire; Rury R Holman; Hermione C Price
Presenting the results of clinical trials to participants.
Clinical medicine (London, England) 2009;9(5):415-6.
2009: D S Lasserson; Paul Glasziou; Rafael Perera; Rury R Holman; Andrew Farmer
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.
Diabetologia 2009;52(10):1990-2000.
2009: Hermione C Price; Christina Dudley; Beryl Barrow; Ian Kennedy; Simon J Griffin; Rury R Holman
Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes.
Family practice 2009;26(5):351-8.
2009: Rebecca K Simmons; Ruth L Coleman; Hermione C Price; Rury R Holman; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.
Diabetes care 2009;32(4):708-13.
2009: Hermione C Price; Rury R Holman
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Nature clinical practice. Cardiovascular medicine 2009;6(3):168-9.
2009: H C Price; Ruth L Coleman; Richard J Stevens; Rury R Holman
Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.
Diabetologia 2009;52(3):394-7.
2009: Andrew Farmer; A N Wade; David P French; Judit Simon; Patricia Yudkin; Alastair M Gray; A Craven; L Goyder; Rury R Holman; David Mant; Ann Louise Kinmonth; H A W Neil
Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial.
Health technology assessment (Winchester, England) 2009;13(15):iii-iv, ix-xi, 1-50.
2009: Janine Hartweg; Andrew Farmer; Rury R Holman; Andrew Neil
Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.
Current opinion in lipidology 2009;20(1):30-8.
2009: Rury R Holman; S Paul; Andrew Farmer; L Tucker; Irene M Stratton; H A W Neil
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Diabetologia 2009;52(1):50-9.
2009: Anna L Gloyn; M van de Bunt; Irene M Stratton; Lorne Lonie; L Tucker; Sian Ellard; Rury R Holman
Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.
Diabetologia 2009;52(1):172-4.
2009: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert S Sherwin; Bernard Zinman
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes care 2009;32(1):193-203.
2009: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert S Sherwin; B Zinman
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia 2009;52(1):17-30.
2008: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; H A W Neil; David R Matthews
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
The New England journal of medicine 2008;359(15):1565-76.
2008: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H A W Neil
10-year follow-up of intensive glucose control in type 2 diabetes.
The New England journal of medicine 2008;359(15):1577-89.
2008: Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
American heart journal 2008;156(4):623-32.
2008: Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Diabetes care 2008;31(5):845-51.
2008: Hermione C Price; Lynne Tucker; Simon J Griffin; Rury R Holman
The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial.
Cardiovascular diabetology 2008;7():21.
2008: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert S Sherwin; Bernard Zinman
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes care 2008;31(1):173-5.
2008: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert S Sherwin; Bernard Zinman
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.
Diabetologia 2008;51(1):8-11.
2007: Carole A Cull; Christine C Jensen; Ravi Retnakaran; Rury R Holman
Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.
Circulation 2007;116(19):2119-26.
2007: Rury R Holman; Kerensa I Thorne; Andrew Farmer; Melanie J Davies; Joanne F Keenan; Sanjoy Paul; Jonathan C Levy
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
The New England journal of medicine 2007;357(17):1716-30.
2007: Minal Desai; Carole A Cull; Virginia Horton; Michael R Christie; Ezio Bonifacio; Vito Lampasona; Polly J Bingley; Jonathan C Levy; I R Mackay; P Zimmet; Rury R Holman; Anne Clark
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
Diabetologia 2007;50(10):2052-60.
2007: Janine Hartweg; Andrew Farmer; Rafael Perera; Rury R Holman; H A W Neil
Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes.
Diabetologia 2007;50(8):1593-602.
2007: Ruth L Coleman; Richard J Stevens; Ravi Retnakaran; Rury R Holman
Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.
Diabetes care 2007;30(5):1292-3.
2007: Janine Hartweg; Andrew Farmer; Rury R Holman; H A W Neil
Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.
Diabetologia 2007;50(2):250-8.
2007: Minal Desai; Eleftheria Zeggini; Virginia Horton; Katharine R Owen; Andrew T Hattersley; Jonathan C Levy; Mark Walker; K M Gillespie; Polly J Bingley; Graham A Hitman; Rury R Holman; Mark I McCarthy; Anne Clark
An association analysis of the HLA gene region in latent autoimmune diabetes in adults.
Diabetologia 2007;50(1):68-73.
2006: Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; Mary O'Neill; Bernard Zinman; Giancarlo Viberti
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
The New England journal of medicine 2006;355(23):2427-43.
2006: R Calle; Mark I McCarthy; P Banerjee; Eleftheria Zeggini; Carole A Cull; Kerensa I Thorne; Steven Wiltshire; S Terra; D Meyer; J Richmond; J Mancuso; Patrice M Milos; D Fryburg; Rury R Holman
Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76.
Diabetologia 2006;49(12):2892-9.
2006: Alex D Wright; Carole A Cull; Kenneth M Macleod; Rury R Holman
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
Journal of diabetes and its complications 2006;20(6):395-401.
2006: Timothy Davis; Carole A Cull; Rury R Holman
A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
Diabetes care 2006;29(11):2560; author reply 2560-1.
2006: Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles R Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey L Probstfield; George Fodor; Rury R Holman
Effect of ramipril on the incidence of diabetes.
The New England journal of medicine 2006;355(15):1551-62.
2006: David M Nathan; John B Buse; Mayer B Davidson; Robert J Heine; Rury R Holman; Robert S Sherwin; Bernard Zinman
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes care 2006;29(8):1963-72.
2006: Steven E Kahn; Bernard Zinman; Steven M Haffner; Mary O'Neill; Barbara G Kravitz; Dahong Yu; Freed Martin; William H Herman; Rury R Holman; Nigel P Jones; John M Lachin; Giancarlo Viberti
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes 2006;55(8):2357-64.
2006: David M Nathan; John B Buse; Mayer B Davidson; Robert J Heine; Rury R Holman; Robert S Sherwin; Bernard Zinman
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia 2006;49(8):1711-21.
2006: Irene M Stratton; Carole A Cull; Amanda I Adler; David R Matthews; H A W Neil; Rury R Holman
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
Diabetologia 2006;49(8):1761-9.
2006: Christoph Stettler; Sabin Allemann; Peter Jüni; Carole A Cull; Rury R Holman; Matthias Egger; Stephan Krähenbühl; Peter Diem
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
American heart journal 2006;152(1):27-38.
2006: Philip M Clarke; Judit Simon; Carole A Cull; Rury R Holman
Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36.
Diabetes care 2006;29(7):1506-11.
2006: Minal Desai; Eleftheria Zeggini; Virginia Horton; Katharine R Owen; Andrew T Hattersley; Jonathan C Levy; Graham A Hitman; Mark Walker; Rury R Holman; Mark I McCarthy; Anne Clark
The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults.
Diabetes 2006;55(6):1890-4.
2006: Ravi Retnakaran; Carole A Cull; Kerensa I Thorne; Amanda I Adler; Rury R Holman
Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
Diabetes 2006;55(6):1832-9.
2006: Rury R Holman
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
Metabolism: clinical and experimental 2006;55(5 Suppl 1):S2-5.
2005: Margaret J Thomason; J P Biddulph; Carole A Cull; Rury R Holman
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(8):1031-6.
2005: Rury R Holman; Ruth L Coleman; Brian S F Shine; Richard J Stevens
Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes.
Diabetes care 2005;28(7):1796-7.
2005: Michael N Cook; Cynthia J Girman; Peter P Stein; Charles M Alexander; Rury R Holman
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
Diabetes care 2005;28(5):995-1000.
2005: Philip M Clarke; Alastair M Gray; Andrew Briggs; Richard J Stevens; David R Matthews; Rury R Holman
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Diabetologia 2005;48(5):868-77.
2005: Gian Franco Bottazzo; Emanuele Bosi; Carole A Cull; E Bonifacio; M Locatelli; P Zimmet; I R Mackay; Rury R Holman
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
Diabetologia 2005;48(4):703-8.
2005: Timothy Davis; A D Wright; Z M Mehta; Carole A Cull; Irene M Stratton; Gian Franco Bottazzo; Emanuele Bosi; Ian R Mackay; Rury R Holman
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
Diabetologia 2005;48(4):695-702.
2005: Amanda I Adler; Jonathan C Levy; David R Matthews; Irene M Stratton; G Hines; Rury R Holman
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).
Diabetic medicine : a journal of the British Diabetic Association 2005;22(3):306-11.
2005: Richard J Stevens; R L Coleman; Rury R Holman
Framingham risk equations underestimate coronary heart disease risk in diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(2):228.
2004: Carole A Cull; H A W Neil; Rury R Holman
Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Diabetic medicine : a journal of the British Diabetic Association 2004;21(12):1368-71.
2004: David R Matthews; Irene M Stratton; Steve Aldington; Rury R Holman; Eva M Kohner
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Archives of ophthalmology 2004;122(11):1631-40.
2004: Philip M Clarke; Alastair M Gray; Andrew Briggs; Andrew Farmer; Paul Fenn; Richard J Stevens; David R Matthews; Irene M Stratton; Rury R Holman
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
Diabetologia 2004;47(10):1747-59.
2004: Richard J Stevens; Ruth L Coleman; Amanda I Adler; Irene M Stratton; David R Matthews; Rury R Holman
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
Diabetes care 2004;27(1):201-7.
2004: Nina Mohanlal; Rury R Holman
A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test.
Diabetes care 2004;27(1):89-94.
2003: D R Hadden; Carole A Cull; D J Croft; Rury R Holman
Poor pregnancy outcome for women with Type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2003;20(6):506-7.
2003: Timothy Davis; Z Mehta; Ian R Mackay; Carole A Cull; David G Bruce; Shahnaz Fida; Merrill J Rowley; Rury R Holman
Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2003;20(3):198-204.
2003: Amanda I Adler; Richard J Stevens; Irene Stratton; Rudy Bilous; Carole A Cull; Rury R Holman
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Kidney international 2003;63(1):225-32.
2002: Richard J Stevens; Irene M Stratton; Rury R Holman
UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
Journal of diabetes and its complications 2002;16(6):371-6.
2002: Giancarlo Viberti; Steven E Kahn; Douglas A Greene; William H Herman; Bernard Zinman; Rury R Holman; Steven M Haffner; Daniel Levy; John M Lachin; Rhona A Berry; Mark A Heise; Nigel P Jones; Freed Martin
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Diabetes care 2002;25(10):1737-43.
2002: Stephen Colagiuri; Carole A Cull; Rury R Holman
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.
Diabetes care 2002;25(8):1410-7.
2002: Viti Kothari; Richard J Stevens; Amanda I Adler; Irene M Stratton; Irene Stratton; H A W Neil; Rury R Holman
UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.
Stroke; a journal of cerebral circulation 2002;33(7):1776-81.
2002: Amanda I Adler; Richard J Stevens; Andrew Neil; Irene M Stratton; Andrew J M Boulton; Rury R Holman
UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.
Diabetes care 2002;25(5):894-9.
2002: Anna L Gloyn; Minal Desai; Anne Clark; Jonathan C Levy; Rury R Holman; Timothy M Frayling; Andrew T Hattersley; Stephen J H Ashcroft
Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.
Diabetologia 2002;45(4):580-3.
2002: Alex Wright; A C Felix Burden; Richard B Paisey; Carole A Cull; Rury R Holman
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Diabetes care 2002;25(2):330-6.
2001: Y Hashim; D Shepherd; Steven Wiltshire; Rury R Holman; Jonathan C Levy; Anne Clark; Carole A Cull
Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.
Diabetologia 2001;44(12):2227-30.
2001: Timothy Davis; Carole A Cull; Rury R Holman
Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
Diabetes care 2001;24(7):1167-74.
2001: Eva M Kohner; Irene M Stratton; Steve Aldington; Rury R Holman; David R Matthews
Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
Diabetic medicine : a journal of the British Diabetic Association 2001;18(3):178-84.
2001: Irene M Stratton; Eva M Kohner; Steve Aldington; RC Turner; Rury R Holman; Irene Stratton; David R Matthews
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
Diabetologia 2001;44(2):156-63.
2000: Amanda I Adler; Irene M Stratton; H A W Neil; J S Yudkin; David R Matthews; Carole A Cull; A D Wright; RC Turner; Rury R Holman
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
BMJ (Clinical research ed.) 2000;321(7258):412-9.
2000: Irene M Stratton; Amanda I Adler; H A W Neil; David R Matthews; Irene Stratton; Carole A Cull; D Hadden; RC Turner; Rury R Holman
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
BMJ (Clinical research ed.) 2000;321(7258):405-12.
2000: Irene Stratton; Irene M Stratton; Carole A Cull; Valeria Frighi; E A Eeley; David R Matthews; Rury R Holman; RC Turner; H A W Neil
Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.
Diabetic medicine : a journal of the British Diabetic Association 2000;17(7):518-23.
1999: Amanda I Adler; H A W Neil; Irene Stratton; Rury R Holman; RC Turner
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47).
American heart journal 1999;138(5 Pt 1):S353-9.
1999: RC Turner; Carole A Cull; Valeria Frighi; Rury R Holman
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
JAMA : the journal of the American Medical Association 1999;281(21):2005-12.
1999: Rury R Holman; Carole A Cull; RC Turner
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
Diabetes care 1999;22(6):960-4.
1999: Timothy Davis; H Millns; Irene M Stratton; Rury R Holman; RC Turner
Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.
Archives of internal medicine 1999;159(10):1097-103.
1999: RC Turner; Rury R Holman
Metformin and risk of cardiovascular disease.
Cardiology 1999;91(3):203-4.
1998: Rury R Holman
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states.
Diabetes research and clinical practice 1998;40 Suppl():S21-5.
1998: J Rachman; M J Payne; Jonathan C Levy; BA Barrow; Rury R Holman; RC Turner
Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
Diabetes care 1998;21(5):810-6.
1998: David R Matthews; Carole A Cull; Irene M Stratton; Rury R Holman; RC Turner
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Diabetic medicine : a journal of the British Diabetic Association 1998;15(4):297-303.
1998: RC Turner; H Millns; H A W Neil; Irene M Stratton; Irene Stratton; David R Matthews; Rury R Holman
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
BMJ (Clinical research ed.) 1998;316(7134):823-8.
1998: Eva M Kohner; Steve Aldington; Irene M Stratton; S E Manley; Rury R Holman; David R Matthews; RC Turner
United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.
Archives of ophthalmology 1998;116(3):297-303.
1997: S Karunakaran; MS Hammersley; RJ Morris; RC Turner; Rury R Holman
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Metabolism: clinical and experimental 1997;46(12 Suppl 1):56-60.
1997: P A Dyson; MS Hammersley; RJ Morris; Rury R Holman; RC Turner
The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose.
Metabolism: clinical and experimental 1997;46(12 Suppl 1):50-5.
1997: MS Hammersley; L C Meyer; RJ Morris; Irene Stratton; RC Turner; Rury R Holman
The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial.
Metabolism: clinical and experimental 1997;46(12 Suppl 1):44-9.
1997: Carole A Cull; Irene Stratton; Irene M Stratton; H A W Neil; I S Ross; Rury R Holman; RC Turner; David R Matthews
Approach to maintaining comparability of biochemical data during long-term clinical trials.
Clinical chemistry 1997;43(10):1913-8.
1997: Timothy Davis; Irene M Stratton; C J Fox; Rury R Holman; RC Turner
U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.
Diabetes care 1997;20(9):1435-41.
1997: RC Turner; H Millns; Rury R Holman
Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
Diabetologia 1997;40 Suppl 2():S121-2.
1997: A Widjaja; Irene M Stratton; R Horn; Rury R Holman; R Turner; G Brabant
UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.
The Journal of clinical endocrinology and metabolism 1997;82(2):654-7.
1996: PJ Saker; Andrew T Hattersley; BA Barrow; MS Hammersley; J A McLellan; Y M Dennis Lo; R J Olds; M D Gillmer; Rury R Holman; RC Turner
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population.
Diabetologia 1996;39(11):1325-8.
1996: RC Turner; Rury R Holman
The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group.
Annals of medicine 1996;28(5):439-44.
1996: E A Eeley; Irene M Stratton; D R Hadden; RC Turner; Rury R Holman
UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
Diabetic medicine : a journal of the British Diabetic Association 1996;13(7):656-62.
1996: R C Tubner; Carole A Cull; Rury R Holman
U.K. prospective diabetes study.
Diabetes care 1996;19(2):182-3.
1996: R C Tubner; Carole A Cull; Rury R Holman
Frequency of hypoglycemic episodes during intensive therapy with human insulin.
Diabetes care 1996;19(2):181-2.
1995: Rury R Holman; RC Turner
Insulin therapy in type II diabetes.
Diabetes research and clinical practice 1995;28 Suppl():S179-84.
1995: RC Turner; Rury R Holman
Lessons from UK prospective diabetes study.
Diabetes research and clinical practice 1995;28 Suppl():S151-7.
1995: Bernard Keavney; C R Dudley; Irene M Stratton; Rury R Holman; David R Matthews; Peter J Ratcliffe; RC Turner
UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.
Diabetologia 1995;38(8):948-52.
1993: Jonathan C Levy; Carole A Cull; Irene M Stratton; Rury R Holman; RC Turner
[The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results].
Journées annuelles de diabétologie de l'Hôtel-Dieu 1993;():123-37.
1991: Anne Clark; S M Yon; E J de Koning; Rury R Holman
Autoantibodies to islet amyloid polypeptide in diabetes.
Diabetic medicine : a journal of the British Diabetic Association 1991;8(7):668-73.
1990: RC Turner; Rury R Holman
Insulin use in NIDDM. Rationale based on pathophysiology of disease.
Diabetes care 1990;13(9):1011-20.
1988: Rury R Holman; RC Turner
Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements.
Diabetic medicine : a journal of the British Diabetic Association 1988;5(6):582-8.